HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

A genetic risk score is associated with hepatic triglyceride content and non-alcoholic steatohepatitis in Mexicans with morbid obesity.

AbstractBACKGROUND AND AIMS:
Genome-wide association studies have identified single nucleotide polymorphisms (SNPs) near/in PNPLA3, NCAN, LYPLAL1, PPP1R3B, and GCKR genes associated with non-alcoholic fatty liver disease (NAFLD) mainly in individuals of European ancestry. The aim of the study was to test whether these genetic variants and a genetic risk score (GRS) are associated with elevated liver fat content and non-alcoholic steatohepatitis (NASH) in Mexicans with morbid obesity.
METHODS:
130 morbidly obese Mexican individuals were genotyped for six SNPs in/near PNPLA3, NCAN, LYPLAL1, PPP1R3B, and GCKR genes. Hepatic fat content [triglyceride (HTG) and total cholesterol (HTC)] was quantified directly in liver biopsies and NASH was diagnosed by histology. A GRS was tested for association with liver fat content and NASH using logistic regression models. In addition, 95 ancestry-informative markers were genotyped to estimate population admixture proportions.
RESULTS:
After adjusting for age, sex and admixture, PNPLA3, LYPLAL1, GCKR and PPP1R3B polymorphisms were associated with higher HTG content (P < 0.05 for PNPLA3, LYPLAL1, GCKR polymorphisms and P = 0.086 for PPP1R3B). The GRS was significantly associated with higher HTG and HTC content (P = 1.0 × 10(-4) and 0.048, respectively), steatosis stage (P = 0.029), and higher ALT levels (P = 0.002). Subjects with GRS ≥ 6 showed a significantly increased risk of NASH (OR = 2.55, P = 0.045) compared to those with GRS ≤ 5. However, the GRS did not predict NASH status, as AUC of ROC curves was 0.56 (P = 0.219).
CONCLUSION:
NAFLD associated loci in Europeans and a GRS based on these loci contribute to the accumulation of hepatic lipids and NASH in morbidly obese Mexican individuals.
AuthorsPaola León-Mimila, Joel Vega-Badillo, Roxana Gutiérrez-Vidal, Hugo Villamil-Ramírez, Teresa Villareal-Molina, Elena Larrieta-Carrasco, Blanca E López-Contreras, Luis R Macías Kauffer, Diana G Maldonado-Pintado, Nahúm Méndez-Sánchez, Armando R Tovar, Rogelio Hernández-Pando, Rafael Velázquez-Cruz, Francisco Campos-Pérez, Carlos A Aguilar-Salinas, Samuel Canizales-Quinteros
JournalExperimental and molecular pathology (Exp Mol Pathol) Vol. 98 Issue 2 Pg. 178-83 (Apr 2015) ISSN: 1096-0945 [Electronic] Netherlands
PMID25597287 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Adaptor Proteins, Signal Transducing
  • Chondroitin Sulfate Proteoglycans
  • GCKR protein, human
  • Lectins, C-Type
  • Membrane Proteins
  • Nerve Tissue Proteins
  • Neurocan
  • Triglycerides
  • NCAN protein, human
  • Cholesterol
  • Lipase
  • adiponutrin, human
  • Lysophospholipase
  • LYPLAL1 protein, human
  • PPP1R3B protein, human
  • Protein Phosphatase 1
Topics
  • Adaptor Proteins, Signal Transducing (genetics)
  • Adult
  • Cholesterol (analysis, metabolism)
  • Chondroitin Sulfate Proteoglycans (genetics)
  • Female
  • Gene Frequency
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Humans
  • Lectins, C-Type (genetics)
  • Lipase (genetics)
  • Liver (metabolism)
  • Lysophospholipase (genetics)
  • Male
  • Membrane Proteins (genetics)
  • Mexico
  • Nerve Tissue Proteins (genetics)
  • Neurocan
  • Non-alcoholic Fatty Liver Disease (genetics, metabolism, pathology)
  • Obesity, Morbid (genetics, metabolism, pathology)
  • Polymorphism, Single Nucleotide
  • Protein Phosphatase 1 (genetics)
  • Triglycerides (analysis, metabolism)
  • White People (genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: